
The CardioMEMS European Monitoring Study for Heart Failure (MEMS‐HF) investigated the safety and efficacy of pulmonary artery pressure (PAP)‐guided remote patient management (RPM) in New York Heart Association (NYHA) class III outpatients with at least one heart failure hospitalization (HFH) during the previous 12 months. This pre‐specified subgroup analysis investigated whether RPM effects depended on the presence and subtype of pulmonary hypertension (PH). Outpatients with NYHA class III symptoms with at least one HFH during 1-year pre‐implant benefitted significantly from PAP‐guided RPM during post‐implant follow‐up irrespective of presence or subtype of PH at baseline.
Like
Save
Share